Patent ID: 11945797
Assignee: MISSION THERAPEUTICS LIMITED
Field: Organic fine chemistry (Chemistry)
Classification: CPC C  A | IPC C

Claim 0:
1. A compound, having the formula (IB):, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, wherein:
R1a, R1b, R1c, R1d, R1e and R1f each independently represent hydrogen, optionally substituted C1-C6 alkyl or optionally substituted C3-C4 cycloalkyl;
R2y represents hydrogen or optionally substituted C1-C6 alkyl;
A represents a 9 to 10-membered bicyclic ring selected from a heteroaryl, heterocyclyl and aryl ring;
L represents a covalent bond, an oxygen atom, a sulphur atom, -OR8—, —SO—, —SO2—, —CO—, —C(O)O—, C0-C3 alkylene-CONR6—C0-C3 alkylene-, —C0-C3 alkylene-NR6—C0-C3 alkylene, —C0-C3 alkylene-NR6CO—C0-C3 alkylene, —C0-C3 alkylene-NR6CONR7—C0-C3 alkylene, —C0-C3 alkylene-SO2NR6—C0-C3 alkylene, —C0-C3 alkylene-NR6SO2—C0-C3 alkylene, —C0-C3 alkylene-NR6SO2NR7—C0-C3 alkylene, —C0-C3 alkylene-NR6C(O)O—C0-C3 alkylene, —C0-C3 alkylene-NR6C(O)OR7—C0-C3 alkylene, optionally substituted —C1-C6 alkylene or optionally substituted —C2-C6 alkenylene;
B represents a 3 to 10-membered monocyclic or bicyclic heterocyclyl, heteroaryl, cycloalkyl or aryl ring;
wherein A is optionally substituted with one to four substituents, each independently selected from halogen, cyano, oxo, nitro, hydroxyl, —SR3, —NR3R4, —CONR3R4, —NR3COR4, —NR3CONR4R5, —COR5, —C(O)OR3, —SO2R3, —SO2NR3R4, —NR3SO2R4, NR3SO2NR4R5, —NR3C(O)OR4, optionally substituted —C1-C6 alkyl, optionally substituted —C1-C6 alkoxy, optionally substituted —C2-C6 alkenyl, optionally substituted —C2-C6 alkynyl and C3-C4 cycloalkyl;
wherein B is optionally substituted with one to four substituents independently, each selected from halogen, cyano, oxo, nitro, hydroxyl, —SR9, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, -Q1a-NR9CONR10R11, -Q1a-NR9R10, -Q1a-COR9, -Q1a-NR9COR10, -Q1a-NR9C(O)OR10, -Q1a-SO2R9, -Q1a-CONR9R10, -Q1a-CO2R9, -Q1a-SO2NR9R10, -Q1a-SO2R9, -Q1a-CONR9R10, -Q1a-CO2R9, -Q1a-SO2NR9R10, -Q1a-NR9SO2R10 and -Q1a-NR9SO2NR10R11;
Q1a represents a covalent bond, optionally substituted C1-C6 alkylene or optionally substituted C2-C6 alkenylene;
R3, R4 and R5 each independently represent hydrogen or optionally substituted C1-C6 alkyl;
R6 and R7 each independently represent hydrogen or optionally substituted C1-C6 alkyl;
R8 represents optionally substituted C1-C6 alkylene or optionally substituted C2-C6 alkenylene;
R9, R10 and R11 each independently represent hydrogen or optionally substituted C1-C6 alkyl; and
wherein C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkylene and C2-C6 alkenylene of R1a, R1b, R1c, R1d, R1e, R1f, R2y, R3, R4, R5, R6, R7, R8, R9, R10, R11, A, B, L and Q1a and C3-C4 cycloalkyl of R1a, R1b, R1c, R1d, R1e and R1f, are each optionally substituted with one to four substituents independently selected from halogen, hydroxyl, thiol, cyano, amino, amido, nitro and SF5;
with the proviso that:
(i) A cannot be triazolopyridazinyl, triazolopyridinyl, imidazotriazinyl, imidazopyrazinyl, pyrrolopyrimidinyl or [1,2,4]triazolo[1,5-a]pyrazinyl, (ii) B cannot be substituted with phenoxyl, and (iii) B cannot be cyclopentyl when L is an oxygen atom.